Table 6 Vaccine completeness at age 2 and 7 for IEI patients by age at diagnosis, type of primary immune deficiency, use of immunoglobulin replacement therapy (Nā=ā95*)
| Ā | Overall vaccine completeness % (n) | Completeness of MMR/MMRV % (n) | Completeness of DTaP-Hib-IPV Vaccination % (n) | Completeness of DTaP/TdaP % (n) | |||
|---|---|---|---|---|---|---|---|
Age 2 | Age 7 | Age 2 | Age 7 | Age 2 | Age 7 | ||
Age at IEI diagnosis (Nā=āAge 2,Age 7) | Age at diagnosis atā<ā1Ā year (Nā=ā28,13) | 32% (9) | 23% (3) | 57% (16) | 39% (5) | 64% (18) | 62% (8) |
| Ā | Age at diagnosis 1 toā<ā4Ā years (Nā=ā36,23) | 36% (13) | 4% (1) | 75% (27) | 30% (7) | 53% (19) | 26% (6) |
| Ā | Age at diagnosisāā„ā4Ā years (Nā=ā13,13) | 46% (6) | 15% (2) | 85% (11) | 62% (8) | 69% (9) | 46% (6) |
| Ā | Age at diagnosis unavailable (Nā=ā18,8) | 61% (11) | 13% (1) | 89% (16) | 25% (2) | 89% (16) | 63% (5) |
Type of IEI | Immunodeficiencies affecting cellular and humoral immunity (Nā=ā13,6) | 23% (3) | 17% (1) | 62% (8) | 17% (1) | 54% (7) | 50% (3) |
| Ā | Combined immunodeficiency with associated or syndromic features (Nā=ā35,21) | 20% (7) | 5% (1) | 66% (23) | 43% (9) | 63% (22) | 38% (8) |
| Ā | Predominantly antibody deficiencies (Nā=ā43,27) | 58% (25) | 15% (4) | 81% (35) | 41% (11) | 67% (29) | 41% (11) |
| Ā | Defects in innate/phagocyte immunity (Nā=ā4,3) | 100% (4) | 33% (1) | 100% (4) | 33% (1) | 100% (4) | 100% (3) |
Immunoglobulin replacement therapy | Yes (Nā=ā54,30) | 39% (21) | 10% (3) | 70% (38) | 33% (10) | 67% (36) | 33% (10) |
| Ā | No (Nā=ā40,27) | 45% (18) | 15% (4) | 80% (32) | 46% (12)** | 65% (26) | 58% (15)** |